316 results on '"van de Wetering, Marianne"'
Search Results
102. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters
- Author
-
Schoot, Reineke A, primary, Kremer, Leontien CM, additional, van de Wetering, Marianne D, additional, and van Ommen, Cornelia H, additional
- Published
- 2013
- Full Text
- View/download PDF
103. Influenza vaccination in children being treated with chemotherapy for cancer
- Author
-
Goossen, Ginette M, primary, Kremer, Leontien CM, additional, and van de Wetering, Marianne D, additional
- Published
- 2013
- Full Text
- View/download PDF
104. Diversity in renal function monitoring and dose modifications during treatment for childhood cancer: A call for standardization
- Author
-
Blufpand, Hester N., primary, Hes, Nicole, additional, Bökenkamp, Arend, additional, van de Wetering, Marianne D., additional, and Kaspers, Gertjan J.L., additional
- Published
- 2013
- Full Text
- View/download PDF
105. Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer
- Author
-
Schoot, Reineke A, primary, van Dalen, Elvira C, additional, van Ommen, Cornelia H, additional, and van de Wetering, Marianne D, additional
- Published
- 2013
- Full Text
- View/download PDF
106. Fertility preservation in children, adolescents, and young adults with cancer: Quality of clinical practice guidelines and variations in recommendations.
- Author
-
Font‐Gonzalez, Anna, Mulder, Renée L., Loeffen, Erik A.H., Byrne, Julianne, van Dulmen‐den Broeder, Eline, van den Heuvel‐Eibrink, Marry M., Hudson, Melissa M., Kenney, Lisa B., Levine, Jennifer M., Tissing, Wim J.E., van de Wetering, Marianne D., and Kremer, Leontien C. M.
- Subjects
CANCER in adolescence ,CHILDHOOD cancer ,ADOLESCENT health ,CHILDREN'S health ,JUVENILE diseases - Abstract
Background: Fertility preservation care for children, adolescents, and young adults (CAYAs) with cancer is not uniform among practitioners. To ensure high-quality care, evidence-based clinical practice guidelines (CPGs) are essential. The authors identified existing CPGs for fertility preservation in CAYAs with cancer, evaluated their quality, and explored differences in recommendations.Methods: A systematic search in PubMed (January 2000-October 2014); guideline databases; and Web sites of oncology, pediatric, and fertility organizations was performed. Two reviewers evaluated the quality of the identified CPGs using the Appraisal of Guidelines for Research and Evaluation II Instrument (AGREE II). From high-quality CPGs, the authors evaluated concordant and discordant areas among the recommendations.Results: A total of 25 CPGs regarding fertility preservation were identified. The average AGREE II domain scores (scale of 0%-100%) varied from 15% on applicability to 100% on clarity of presentation. The authors considered 8 CPGs (32%) to be of high quality, which was defined as scores ≥60% in any 4 domains. Large variations in the recommendations of the high-quality CPGs were observed, with 87.2% and 88.6%, respectively, of discordant guideline areas among the fertility preservation recommendations for female and male patients with cancer.Conclusions: Only approximately one-third of the identified CPGs were found to be of sufficient quality. Of these CPGs, the fertility preservation recommendations varied substantially, which can be a reflection of inadequate evidence for specific recommendations, thereby hindering the ability of providers to deliver high-quality care. CPGs including a transparent decision process for fertility preservation can help health care providers to deliver optimal and uniform care, thus improving the quality of life of CAYAs with cancer and cancer survivors. Cancer 2016;122:2216-23. © 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
107. Mannose-binding Lectin and the Risk of HIV Transmission and Disease Progression in Children
- Author
-
Israëls, Joël, primary, Scherpbier, Henriette J., additional, Frakking, Florine N. J., additional, van de Wetering, Marianne D., additional, Kremer, Leontien C. M., additional, and Kuijpers, Taco W., additional
- Published
- 2012
- Full Text
- View/download PDF
108. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia
- Author
-
van Dalen, Elvira C, primary, Mank, Arno, additional, Leclercq, Edith, additional, Mulder, Renée L, additional, Davies, Michelle, additional, Kersten, Marie José, additional, and van de Wetering, Marianne D, additional
- Published
- 2012
- Full Text
- View/download PDF
109. Differentiated Thyroid Carcinoma After 131I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases
- Author
-
van Santen, Hanneke M., primary, Tytgat, Godelieve A.M., additional, van de Wetering, Marianne D., additional, van Eck-Smit, Berthe L.F., additional, Hopman, Saskia M.J., additional, van der Steeg, Alida F., additional, Nieveen van Dijkum, Els J.M., additional, and van Trotsenburg, A.S. Paul, additional
- Published
- 2012
- Full Text
- View/download PDF
110. Obituary of a Very Special Doctor, Dr Jan de Kraker (October 18, 1944 to January 19, 2012)
- Author
-
van de Wetering, Marianne D., primary, D’Angio, Giulio, additional, and Caron, Huib, additional
- Published
- 2012
- Full Text
- View/download PDF
111. Empirical antibiotic therapy for febrile neutropenia in pediatric cancer patients
- Author
-
Miedema, Karin GE, primary, van de Wetering, Marianne D, additional, Naeije, Leonie, additional, van den Heuvel, Edwin R, additional, and Tissing, Wim JE, additional
- Published
- 2012
- Full Text
- View/download PDF
112. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
- Author
-
Gafter-Gvili, Anat, primary, Fraser, Abigail, additional, Paul, Mical, additional, Vidal, Liat, additional, Lawrie, Theresa A, additional, van de Wetering, Marianne D, additional, Kremer, Leontien CM, additional, and Leibovici, Leonard, additional
- Published
- 2012
- Full Text
- View/download PDF
113. Systemic treatments for the prevention of venous thrombo-embolic events in pediatric cancer patients with tunnelled central venous catheters
- Author
-
Schoot, Reineke A, primary, Kremer, Leontien CM, additional, van de Wetering, Marianne D, additional, and van Ommen, Cornelia H, additional
- Published
- 2011
- Full Text
- View/download PDF
114. Supportive Care for Children With Cancer
- Author
-
van de Wetering, Marianne D., primary and Schouten-van Meeteren, Netteke Y.N., additional
- Published
- 2011
- Full Text
- View/download PDF
115. Bronchioloalveolar Adenocarcinoma and Pulmonary Langerhans Cell Histiocytosis in a Patient With MUTYH-Associated Polyposis
- Author
-
von der Thüsen, Jan H., primary, van de Wetering, Marianne D., additional, Westermann, Anneke M., additional, Heideman, Daniëlle A.M., additional, and Thunnissen, Erik, additional
- Published
- 2011
- Full Text
- View/download PDF
116. Antibiotic and other lock treatments for tunnelled central venous catheter related infections in children with cancer
- Author
-
Schoot, Reineke A, primary, van Dalen, Elvira C, additional, van Ommen, Cornelia H, additional, and van de Wetering, Marianne D, additional
- Published
- 2011
- Full Text
- View/download PDF
117. Mannose-Binding Lectin (MBL) Substitution: Recovery of Opsonic Function In Vivo Lags behind MBL Serum Levels
- Author
-
Brouwer, Nannette, primary, Frakking, Florine N. J., additional, van de Wetering, Marianne D., additional, van Houdt, Michel, additional, Hart, Margreet, additional, Budde, Ilona Kleine, additional, Strengers, Paul F. W., additional, Laursen, Inga, additional, Houen, Gunnar, additional, Roos, Dirk, additional, Jensenius, Jens C., additional, Caron, Huib N., additional, Dolman, Koert M., additional, and Kuijpers, Taco W., additional
- Published
- 2009
- Full Text
- View/download PDF
118. Influenza vaccination in children being treated with chemotherapy for cancer
- Author
-
Goossen, Ginette M, primary, Kremer, Leontien CM, additional, and van de Wetering, Marianne D, additional
- Published
- 2009
- Full Text
- View/download PDF
119. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia
- Author
-
Frakking, Florine N.J., primary, Brouwer, Nannette, additional, van de Wetering, Marianne D., additional, Budde, Ilona Kleine, additional, Strengers, Paul F.W., additional, Huitema, Alwin D., additional, Laursen, Inga, additional, Houen, Gunnar, additional, Caron, Huib N., additional, Dolman, Koert M., additional, and Kuijpers, Taco W., additional
- Published
- 2009
- Full Text
- View/download PDF
120. Phase II study on mannan-binding lectin (MBL) substitution in MBL-deficient children with chemotherapy-induced neutropenia
- Author
-
Brouwer, Nannette, primary, Frakking, Florine, additional, van Houdt, Michel, additional, Hart, Margreet, additional, Laursen, Inga, additional, Houen, Gunnar, additional, Budde, Ilona Kleine, additional, Strengers, Paul, additional, Dolman, Koert, additional, van de Wetering, Marianne, additional, Caron, Huib, additional, and Kuijpers, Taco, additional
- Published
- 2007
- Full Text
- View/download PDF
121. Influenza vaccination in children being treated with chemotherapy for cancer
- Author
-
Goossen, Ginette M, primary, Kremer, Leontien CM, additional, and van de Wetering, Marianne D, additional
- Published
- 2007
- Full Text
- View/download PDF
122. Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients
- Author
-
van de Wetering, Marianne D, primary and van Woensel, Job BM, additional
- Published
- 2007
- Full Text
- View/download PDF
123. Low bacterial diet to prevent infection in neutropenic patients
- Author
-
Mank, Arno, primary, Davies, Michelle, additional, Langeveld, Nelia, additional, van de Wetering, Marianne D, additional, and van der Lelie, Hans, additional
- Published
- 2006
- Full Text
- View/download PDF
124. Prognostic factors for progression of childhood optic pathway glioma: A systematic review
- Author
-
Opocher, Enrico, primary, Kremer, Leontien C.M., additional, Da Dalt, Liviana, additional, van de Wetering, Marianne D., additional, Viscardi, Elisabetta, additional, Caron, Huib N., additional, and Perilongo, Giorgio, additional
- Published
- 2006
- Full Text
- View/download PDF
125. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
- Author
-
Gafter-Gvili, Anat, primary, Fraser, Abigail, additional, Paul, Mical, additional, van de Wetering, Marianne D, additional, Kremer, Leontien CM, additional, and Leibovici, Leonard, additional
- Published
- 2005
- Full Text
- View/download PDF
126. Adult respiratory distress syndrome (ARDS) after chemotherapy
- Author
-
van de Wetering, Marianne D., primary and Peper, Jaques A.K., additional
- Published
- 2000
- Full Text
- View/download PDF
127. Differentiated Thyroid Carcinoma After 131I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases.
- Author
-
van Santen, Hanneke M., Tytgat, Godelieve A.M., van de Wetering, Marianne D., van Eck-Smit, Berthe L.F., Hopman, Saskia M.J., van der Steeg, Alida F., Nieveen van Dijkum, Els J.M., and van Trotsenburg, A.S. Paul
- Subjects
THYROID cancer treatment ,NEUROBLASTOMA ,POTASSIUM iodide ,HYPOTHYROIDISM in children ,MIBG (Chemical) ,PHYSIOLOGICAL effects of radioactivity ,PEDIATRIC endocrinology ,THYROID cancer ,PROGNOSIS - Abstract
Background: It is well known that the thyroid gland is sensitive to the damaging effects of irradiation (X-radiation or
131 I¯). For this reason, during exposure to131 I- metaiodobenzylguanidine (MIBG) in children with neuroblastoma (NBL), the thyroid gland is protected against radiation damage by the administration of either potassium iodide (KI) or a combination of KI, thyroxine, and methimazole. Although hypothyroidism and benign thyroid nodules are frequently encountered during follow-up of these children, differentiated thyroid carcinoma (DTC) has never been reported after treatment with131 I-MIBG in children who have not been given external beam irradiation. Here, we describe the first two cases of DTC after131 I-MIBG-therapy. Patient Findings: A 6-year-old boy, treated with131 I-MIBG for NBL at the age of 4 months, and a 13-year-old girl, treated at the age of 9 months, were both diagnosed with DTC at 5 and 12 years after131 I-MIBG treatment, respectively. Both children received thyroid protection during exposure to131 I-MIBG. In each child DTC was discovered in nonpalpable nodules by thyroid ultrasound. Summary: The first two pediatric patients with DTC after treatment with131 I-MIBG are reported. Conclusions: Both these cases of DTC after131 I-MIBG for childhood NBL underline the importance of adequate thyroid protection against radiation exposure during treatment for NBL. Children who have been treated with131 I-MIBG should be given life-long follow-up, not only with regard to thyroid function, but also with surveillance for the development of thyroid nodules and thyroid cancer. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
128. Development of pediatric oncology supportive care indicators: Evaluation of febrile neutropenia care in the north of the Netherlands.
- Author
-
ten Berg, Sanne, Loeffen, Erik A. H., de Wetering, Marianne D., Martens, Daniëlle H. J., Ede, Carla M., Kremer, Leontien C. M., Tissing, Wim J. E., van de Wetering, Marianne D, and van Ede, Carla M
- Published
- 2019
- Full Text
- View/download PDF
129. Prognostication in advanced cancer: update and directions for future research.
- Author
-
Hui, David, Naberhuis, Jane, Bruera, Eduardo, Paiva, Carlos Eduardo, Del Fabbro, Egidio G., Steer, Christopher, van de Wetering, Marianne, Fernández-Ortega, Paz, Morita, Tatsuya, Mori, Masanori, and Suh, Sang-Yeon
- Subjects
- *
LIFE expectancy , *PALLIATIVE treatment , *TREATMENT effectiveness , *CANCER treatment , *CANCER - Abstract
The objective of this review is to provide an update on prognostication in patients with advanced cancer and to discuss future directions for research in this field. Accurate prognostication of survival for patients with advanced cancer is vital, as patient life expectancy informs many important personal and clinical decisions. The most common prognostic approach is clinician prediction of survival (CPS) using temporal, surprise, or probabilistic questions. The surprise and probabilistic questions may be more accurate than the temporal approach, partly by limiting the time frame of prediction. Prognostic models such as the Glasgow Prognostic Score (GPS), Palliative Performance Scale (PPS), Palliative Prognostic Score (PaP), Palliative Prognostic Index (PPI), or Prognosis in Palliative Care Study (PiPS) predictor model may augment CPS. However, care must be taken to select the appropriate tool since prognostic accuracy varies by patient population, setting, and time frame of prediction. In addition to life expectancy, patients and caregivers often desire that expected treatment outcomes and bodily changes be communicated to them in a sensible manner at an appropriate time. We propose the following 10 major themes for future prognostication research: (1) enhancing prognostic accuracy, (2) improving reliability and reproducibility of prognosis, (3) identifying the appropriate prognostic tool for a given setting, (4) predicting the risks and benefits of cancer therapies, (5) predicting survival for pediatric populations, (6) translating prognostic knowledge into practice, (7) understanding the impact of prognostic uncertainty, (8) communicating prognosis, (9) clarifying outcomes associated with delivery of prognostic information, and (10) standardizing prognostic terminology. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
130. Venous thromboembolic disease in pediatric malignancies: Epidemiology and prevention
- Author
-
Klaassen, Irene L. M., Middeldorp, Saskia, Fijnvandraat, Karin, van Ommen, C. H., van de Wetering, Marianne D., Paediatric Infectious Diseases / Rheumatology / Immunology, Graduate School, Amsterdam Reproduction & Development (AR&D), and ACS - Pulmonary hypertension & thrombosis
- Published
- 2019
131. Perfect pitstops: Towards evidence-based supportive care in children with cancer
- Author
-
Loeffen, Erik, Tissing, Wim, Kremer, Leontien C. M., and van de Wetering, Marianne
- Abstract
In de afgelopen decennia is er enorme vooruitgang geboekt in de behandeling van kinderkanker, waardoor momenteel ruim drie op de vier kinderen genezen van deze ziekte. Toch gaan er nog kinderen met kanker dood; de meeste door de ziekte zelf, maar een op de vijf overlijdens komt door bijwerkingen van de behandeling. Manier vinden om de bijwerkingen beter te voorkomen en behandelen is een essentiële stap naar nog betere uitkomsten voor kinderen met kanker, betoogt Erik Loeffen in zijn proefschrift “Perfect Pitstops”. De behandelingen van kinderkanker hebben allerlei mogelijke bijwerkingen, zoals pijn, haaruitval, angst, en infecties. De ondersteunende zorg bij kinderkanker richt zich op het voorkomen en behandelen van deze bijwerkingen. Erik Loeffen toonde aan dat er momenteel grote variaties bestaan in de ondersteunende zorg, wat ertoe leidt dat niet alle kinderen de best mogelijke zorg krijgen. Om de ondersteunende zorg zo goed en uniform mogelijk te krijgen is het belangrijk richtlijnen te ontwikkelen die zich baseren op wetenschappelijk bewijs. In zijn proefschrift heeft Erik Loeffen verschillende internationale richtlijnen voor ondersteunende zorg ontwikkeld, bijvoorbeeld over het verminderen van angst en pijn tijdens prikken. Ook is verkend hoe deze richtlijnen succesvol in de praktijk gezet kunnen worden. Daarnaast heeft Erik Loeffen gekeken naar welke kinderen er sterven aan bijwerkingen, om deze sterfte in de toekomst hopelijk te kunnen verlagen. Samenvattend pleit Erik Loeffen voor het verbeteren van de ondersteunende zorg bij kinderen met kanker, om zo de sterfte te verlagen en de kwaliteit van leven tijdens en na behandeling te verhogen.
- Published
- 2019
132. Complement activation defects in pediatric oncology patients: Hidden factors contributing to the increased risk of infection
- Author
-
Keizer, Mischa P., Kuijpers, Taco W., Wouters, D., van de Wetering, Marianne D., Graduate School, Paediatric Oncology, and Landsteiner Laboratory
- Published
- 2018
133. Measurement properties of instruments to assess pain in children and adolescents with cancer: a systematic review protocol.
- Author
-
Loeffen, Erik A. H., Stinson, Jennifer N., Birnie, Kathryn A., van Dijk, Monique, Kulkarni, Ketan, Rijsdijk, Mienke, Font-Gonzalez, Anna, Dupuis, L. Lee, van Dalen, Elvira C., Mulder, Renée L., Campbell, Fiona, Tissing, Wim J. E., van de Wetering, Marianne D., and Gibson, Faith
- Subjects
- *
MEASURING instruments , *CHILDHOOD cancer , *META-analysis , *PAIN measurement , *CANCER pain , *EXPERIMENTAL design - Abstract
Background: Pain in children and adolescents with cancer has been identified as an area where many healthcare professionals seek guidance. This protocol details a systematic review whose aim is to explore current knowledge regarding measurement instruments to assess pain (and pain-related distress) in children and adolescents with cancer. After completion of the review, the information will be used in the development of a clinical practice guideline. Methods: We will search four electronic databases (MEDLINE via PubMed, CINAHL, PsycINFO and HaPI). Additional relevant studies will be identified by reference checking and expert consultation. All citations will be screened independently by two reviewers in a three-step approach: first selection based on title, second selection based on abstract, third selection based on full-text. Studies in children and adolescents with cancer that aimed to evaluate the clinimetric properties of an existing pain measurement instrument or to develop a new pain measurement instrument and that include at least one relevant outcome (reliability, validity, responsiveness, interpretability, clinical utility) are eligible for inclusion. For all steps of evidence selection, a detailed list with eligibility criteria will be determined a priori. Data extraction and quality assessment of included studies (according to the COnsensus-based Standards for the selection of health Measurement INstruments, COSMIN criteria) will be conducted independently by two authors. Discussion: This systematic review will provide an overview of the current literature regarding measurement instruments to assess pain in children and adolescents with cancer. This knowledge synthesis will be used to formulate recommendations for clinical practice. Also, by synthesizing existing evidence, knowledge gaps will be identified. Systematic review registration: PROSPERO CRD42017072879 [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
134. Childhood cancer treatment optimization in rhabdomyosarcoma and supportive care
- Author
-
Schoot, Reineke Anna, Caron, Hubertus N., Merks, Johannes H. M., van de Wetering, Marianne D., van Ommen, Cornelia H., Cancer Center Amsterdam, Amsterdam Public Health, and Paediatric Oncology
- Published
- 2015
135. The clinical significance of mannose-binding lectin (MBL) deficiency
- Author
-
Frakking, F.N.J., Kuijpers, Taco W., Dolman, Koert M., van de Wetering, Marianne D., General Paediatrics, Kuijpers, T.W., Dolman, K.M., van de Wetering, M.D., and Faculteit der Geneeskunde
- Subjects
sense organs - Published
- 2008
136. Feasibility and face validity of two patient reported outcome measures for nausea: Preferences of children with cancer.
- Author
-
Haverkate EC, de Vos-Kerkhof E, van de Wetering MD, de Man-van Ginkel JM, Tissing WJE, and Brinksma A
- Subjects
- Humans, Child, Male, Female, Cross-Sectional Studies, Surveys and Questionnaires, Adolescent, Reproducibility of Results, Patient Preference, Neoplasms complications, Nausea, Feasibility Studies, Patient Reported Outcome Measures
- Abstract
Purpose: To optimize recognition and management of nausea in children with cancer using patient reported outcome measures (PROMs) and to identify preferences of children with cancer regarding two validated tools: the Baxter Retching Faces (BARF) scale and the Pediatric Nausea Assessment Tool (PeNAT)., Design and Methods: This quantitative descriptive cross-sectional study (n = 34) used bespoke questionnaires to measure feasibility and face validity of the BARF and the PeNAT. Feasibility included the items: understanding, ease of use, and communication. Face validity was studied in terms of the degree in which the faces of both PROMs corresponded with children's feelings of nausea. A descriptive and comparative analysis of the data was performed., Results: Both the BARF and the PeNAT were rated by the children as feasible, and no significant differences were found. However, regarding the item communication, the PeNAT did not reach the cut-off value (≥80% of all children scored neutral, agree or totally agree on the Likert scale). Regarding face validity, only the BARF reached the cut-off value and corresponded significantly better with children's feelings of nausea than the PeNAT., Conclusion: According to children with cancer, only the BARF is both feasible and meets criteria for face validity. Therefore, the BARF is recommended as a PROM for reporting nausea in children with cancer. However, possible differences between age groups should be taken into account for future research., Practice Implications: This study will help health care professionals in making a patient-centered and informed choice when using a PROM for measuring nausea in children with cancer., Competing Interests: Declaration of competing interest The author(s) declared that there is no conflict of interest. The authors report no actual or potential conflicts of interests. No external or intramural funding was received., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
137. Impact of dexamethasone on transplant-related mortality in pediatric patients: a multi-site, propensity score-weighted, retrospective assessment.
- Author
-
Paw Cho Sing E, Tomlinson GA, Schechter T, Ali M, Phelan R, Rassekh SR, McKinnon K, Bier GA, van de Wetering M, Gomez S, Sung L, and Dupuis LL
- Subjects
- Humans, Retrospective Studies, Female, Male, Child, Child, Preschool, Adolescent, Infant, Hematologic Neoplasms therapy, Hematologic Neoplasms mortality, Cohort Studies, Dexamethasone therapeutic use, Dexamethasone administration & dosage, Propensity Score, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cell Transplantation adverse effects, Transplantation Conditioning methods, Graft vs Host Disease prevention & control, Graft vs Host Disease etiology
- Abstract
Dexamethasone use during hematopoietic cell transplant (HCT) conditioning varies between pediatric centers. This study aimed to estimate the difference in 1-year treatment-related mortality (TRM) between patients who did or did not receive dexamethasone during HCT conditioning. Secondary objectives were to estimate the difference between dexamethasone-exposed and dexamethasone-unexposed groups in 1-year event-free survival (EFS), time to neutrophil engraftment, acute graft-versus-host disease (aGVHD), and invasive fungal disease (IFD) at day + 100. This was a seven-site, international, retrospective cohort study. Patients < 18 years old undergoing their first allogeneic or autologous myeloablative HCT for hematologic malignancy or aplastic anemia between January 1, 2012, and July 31, 2017, were included. To control for potential confounders, propensity score weighting was used to calculate the standardized mean difference for all endpoints. Among 242 patients, 140 received dexamethasone during HCT conditioning and 102 did not. TRM was unaffected by dexamethasone exposure (1.7%; 95% CI - 7.4, 10.2%). Between-group differences in secondary outcomes were small. However, dexamethasone exposure significantly increased possible, probable, and proven IFD incidence (9.0%, 95% CI 0.8, 17.3%). TRM is not increased in pediatric patients who receive dexamethasone during HCT conditioning. Clinicians should consider potential IFD risk when selecting chemotherapy-induced vomiting prophylaxis for pediatric HCT patients., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
138. Alkylating agents-induced gonadotoxicity in prepubertal males: Insights on the clinical and preclinical front.
- Author
-
Sriram S, Macedo T, Mavinkurve-Groothuis A, van de Wetering M, and Looijenga LHJ
- Subjects
- Humans, Male, Child, Infertility, Male chemically induced, Infertility, Male etiology, Infertility, Male diagnosis, Animals, Spermatogenesis drug effects, Spermatogenesis radiation effects, Neoplasms drug therapy, Puberty drug effects, Puberty physiology, Alkylating Agents adverse effects, Alkylating Agents administration & dosage, Testis drug effects, Antineoplastic Agents, Alkylating adverse effects, Antineoplastic Agents, Alkylating administration & dosage
- Abstract
Rising cure rates in pediatric cancer patients warrants an increased attention toward the long-term consequences of the diagnosis and treatment in survivors. Chemotherapeutic agents can be gonadotoxic, rendering them at risk for infertility post-survival. While semen cryopreservation is an option that can be provided for most (post)pubertal boys before treatment, this is unfortunately not an option prepubertal in age, simply due to the lack of spermatogenesis. Over the last couple of years, studies have thus focused on better understanding the testis niche in response to various chemotherapeutic agents that are commonly administered and their direct and indirect impact on the germ cell populations. These are generally compounds that have a high risk of infertility and have been classified into risk categories in curated fertility guidelines. However, with it comes the lack of evidence and the challenge of using informative models and conditions most reflective of the physiological scenario, in short, the appropriate study designs for clinically relevant outcomes. Besides, the exact mechanism(s) of action for many of these "risk" compounds as well as other agents is unclear. Understanding their behavior and effect on the testis niche will pave the way for incorporating new strategies to ultimately combat infertility. Of the various drug classes, alkylating agents pose the highest risk of gonadotoxicity as per previously established studies as well as risk stratification guidelines. Therefore, this review will summarize the findings in the field of male fertility concerning gonadotoxicity of akylating agents as a result of chemotherapy exposure., (© 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2024
- Full Text
- View/download PDF
139. A systematic review on safety and surgical and anesthetic risks of elective abdominal laparoscopic surgery in infants to guide laparoscopic ovarian tissue harvest for fertility preservation for infants facing gonadotoxic treatment.
- Author
-
van der Perk MEM, van der Kooi ALF, Broer SL, Mensink MO, Bos AME, van de Wetering MD, van der Steeg AFW, and van den Heuvel-Eibrink MM
- Abstract
Background: Infertility is an important late effect of childhood cancer treatment. Ovarian tissue cryopreservation (OTC) is established as a safe procedure to preserve gonadal tissue in (pre)pubertal girls with cancer at high risk for infertility. However, it is unclear whether elective laparoscopic OTC can also be performed safely in infants <1 year with cancer. This systematic review aims to evaluate the reported risks in infants undergoing elective laparoscopy regarding mortality, and/or critical events (including resuscitation, circulatory, respiratory, neurotoxic, other) during and shortly after surgery., Methods: This systematic review followed the Preferred reporting Items for Systematic Review and Meta-Analyses (PRISMA) reporting guideline. A systematic literature search in the databases Pubmed and EMbase was performed and updated on February 15
th , 2023. Search terms included 'infants', 'intubation', 'laparoscopy', 'mortality', 'critical events', 'comorbidities' and their synonyms. Papers published in English since 2000 and describing at least 50 patients under the age of 1 year undergoing laparoscopic surgery were included. Articles were excluded when the majority of patients had congenital abnormalities. Quality of the studies was assessed using the QUIPS risk of bias tool., Results: The Pubmed and Embase databases yielded a total of 12,401 unique articles, which after screening on title and abstract resulted in 471 articles to be selected for full text screening. Ten articles met the inclusion criteria for this systematic review, which included 1778 infants <1 years undergoing elective laparoscopic surgery. Mortality occurred once (death not surgery-related), resuscitation in none and critical events in 53/1778 of the procedures., Conclusion: The results from this review illustrate that morbidity and mortality in infants without extensive comorbidities during and just after elective laparoscopic procedures seem limited, indicating that the advantages of performing elective laparoscopic OTC for infants with cancer at high risk of gonadal damage may outweigh the anesthetic and surgical risks of laparoscopic surgery in this age group., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 van der Perk, van der Kooi, Broer, Mensink, Bos, van de Wetering, van der Steeg and van den Heuvel-Eibrink.)- Published
- 2024
- Full Text
- View/download PDF
140. The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients.
- Author
-
van den Bosch CH, Frakking FNJ, Loeffen YGT, van Tinteren H, van der Steeg AFW, Wijnen MHWA, van de Wetering MD, and van der Bruggen JT
- Subjects
- Child, Humans, Prospective Studies, Retrospective Studies, Catheter-Related Infections diagnosis, Catheter-Related Infections etiology, Mucositis, Bacteremia diagnosis, Bacteremia etiology, Sepsis, Neoplasms complications, Neoplasms diagnosis, Catheterization, Central Venous
- Abstract
Background: The aim of this study was to investigate the applicability of the central line-associated bloodstream infection (CLABSI) criteria of the Centers for Disease Control and Prevention in pediatric oncology patients., Methods: Bacteremia episodes from 2020 to 2022 from a prospective cohort of pediatric oncology patients with a central venous catheter were included. Episodes were classified by three medical experts following the CLABSI criteria as either a CLABSI or non-CLABSI (i.e., contamination, other infection source, or mucosal barrier injury-laboratory confirmed bloodstream infection (MBI-LCBI)). Subsequently, they were asked if and why they (dis)agreed with this diagnosis following the criteria. The primary outcome was the percentage of episodes where the experts clinically disagreed with the diagnosis given following the CLABSI criteria., Results: Overall, 84 bacteremia episodes in 71 patients were evaluated. Following the CLABSI criteria, 34 (40%) episodes were classified as CLABSIs and 50 (60%) as non-CLABSIs. In 11 (13%) cases the experts clinically disagreed with the diagnosis following the CLABSI criteria. The discrepancy between the CLABSI criteria and clinical diagnosis was significant; McNemar's test p < .01. Disagreement by the experts with the CLABSI criteria mostly occurred when the experts found an MBI-LCBI a more plausible cause of the bacteremia than a CLABSI due to the presence of a gram negative bacteremia (Pseudomonas aeruginosa n = 3) and/or mucositis., Conclusions: A discrepancy between the CLABSI criteria and the evaluation of the experts was observed. Adding Pseudomonas aeruginosa as an MBI pathogen and incorporating the presence of mucositis in the MBI-LCBI criteria, might increase the applicability., (© 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
141. Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine-a case series.
- Author
-
Schellekens KPJ, Hageman SB, Haverkate EC, van de Wetering MD, Engels FK, Brinksma A, and de Vos-Kerkhof E
- Subjects
- Humans, Child, Retrospective Studies, Lomustine adverse effects, Quality of Life, Nausea chemically induced, Nausea prevention & control, Nausea drug therapy, Vomiting chemically induced, Vomiting drug therapy, Vomiting prevention & control, Antiemetics, Antineoplastic Agents adverse effects, Glioma drug therapy
- Abstract
Purpose: Although lomustine has been used as a chemotherapeutic agent for decades, no recommendation on appropriate chemotherapy-induced nausea and vomiting (CINV) prophylaxis is available. As CINV is considered one of the most bothersome side effects of chemotherapy, adequate prophylaxis is of relevance to improve quality of life during cancer treatment. The aim of this retrospective case series was to report the incidence and severity of CINV in pediatric patients with high-grade glioma treated with lomustine and to formulate recommendations for appropriate CINV prophylaxis., Methods: Pediatric patients treated with lomustine for high-grade glioma according to the ACNS 0423 protocol were identified retrospectively. Two researchers independently reviewed and classified complaints of CINV and administered CINV prophylaxis. Treatment details, tumor localization, and response to therapy were systematically extracted from the patients' files., Results: Seventeen children aged 8-18 years received a median of four cycles of lomustine. CINV complaints and administered prophylaxis were evaluable in all patients. Moderate or severe CINV was observed in 13/17 (76%) patients. Administered prophylactic CINV regimens varied from no prophylaxis to triple-agent combinations., Conclusion: In this case series, we identified lomustine as a highly emetogenic chemotherapeutic agent. According to the current guidelines, CINV prophylaxis with a 5-HT3 receptor antagonist in combination with dexamethasone and (fos)aprepitant is recommended., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
142. A 20-year overview of fertility preservation in boys: new insights gained through a comprehensive international survey.
- Author
-
Duffin K, Neuhaus N, Andersen CY, Barraud-Lange V, Braye A, Eguizabal C, Feraille A, Ginsberg JP, Gook D, Goossens E, Jahnukainen K, Jayasinghe Y, Keros V, Kliesch S, Lane S, Mulder CL, Orwig KE, van Pelt AMM, Poirot C, Rimmer MP, Rives N, Sadri-Ardekani H, Safrai M, Schlatt S, Stukenborg JB, van de Wetering MD, Wyns C, and Mitchell RT
- Abstract
Study Question: Twenty years after the inception of the first fertility preservation programme for pre-pubertal boys, what are the current international practices with regard to cryopreservation of immature testicular tissue?, Summary Answer: Worldwide, testicular tissue has been cryopreserved from over 3000 boys under the age of 18 years for a variety of malignant and non-malignant indications; there is variability in practices related to eligibility, clinical assessment, storage, and funding., What Is Known Already: For male patients receiving gonadotoxic treatment prior to puberty, testicular tissue cryopreservation may provide a method of fertility preservation. While this technique remains experimental, an increasing number of centres worldwide are cryopreserving immature testicular tissue and are approaching clinical application of methods to use this stored tissue to restore fertility. As such, standards for quality assurance and clinical care in preserving immature testicular tissue should be established., Study Design Size Duration: A detailed survey was sent to 17 centres within the recently established ORCHID-NET consortium, which offer testicular tissue cryopreservation to patients under the age of 18 years. The study encompassed 60 questions and remained open from 1 July to 1 November 2022., Participants/materials Setting Methods: Of the 17 invited centres, 16 completed the survey, with representation from Europe, Australia, and the USA. Collectively, these centres have cryopreserved testicular tissue from patients under the age of 18 years. Data are presented using descriptive analysis., Main Results and the Role of Chance: Since the establishment of the first formal fertility preservation programme for pre-pubertal males in 2002, these 16 centres have cryopreserved tissue from 3118 patients under the age of 18 years, with both malignant (60.4%) and non-malignant (39.6%) diagnoses. All centres perform unilateral biopsies, while 6/16 sometimes perform bilateral biopsies. When cryopreserving tissue, 9/16 centres preserve fragments sized ≤5 mm
3 with the remainder preserving fragments sized 6-20 mm3 . Dimethylsulphoxide is commonly used as a cryoprotectant, with medium supplements varying across centres. There are variations in funding source, storage duration, and follow-up practice. Research, with consent, is conducted on stored tissue in 13/16 centres., Limitations Reasons for Caution: While this is a multi-national study, it will not encompass every centre worldwide that is cryopreserving testicular tissue from males under 18 years of age. As such, it is likely that the actual number of patients is even higher than we report. Whilst the study is likely to reflect global practice overall, it will not provide a complete picture of practices in every centre., Wider Implications of the Findings: Given the research advances, it is reasonable to suggest that cryopreserved immature testicular tissue will in the future be used clinically to restore fertility. The growing number of patients undergoing this procedure necessitates collaboration between centres to better harmonize clinical and research protocols evaluating tissue function and clinical outcomes in these patients., Study Funding/competing Interests: K.D. is supported by a CRUK grant (C157/A25193). R.T.M. is supported by an UK Research and Innovation (UKRI) Future Leaders Fellowship (MR/S017151/1). The MRC Centre for Reproductive Health at the University of Edinburgh is supported by MRC (MR/N022556/1). C.L.M. is funded by Kika86 and ZonMW TAS 116003002. A.M.M.v.P. is supported by ZonMW TAS 116003002. E.G. was supported by the Research Program of the Research Foundation-Flanders (G.0109.18N), Kom op tegen Kanker, the Strategic Research Program (VUB_SRP89), and the Scientific Fund Willy Gepts. J.-B.S. is supported by the Swedish Childhood Cancer Foundation (TJ2020-0026). The work of NORDFERTIL is supported by the Swedish Childhood Cancer Foundation (PR2019-0123; PR2022-0115), the Swedish Research Council (2018-03094; 2021-02107), and the Birgitta and Carl-Axel Rydbeck's Research Grant for Paediatric Research (2020-00348; 2021-00073; 2022-00317; 2023-00353). C.E is supported by the Health Department of the Basque Government (Grants 2019111068 and 2022111067) and Inocente Inocente Foundation (FII22/001). M.P.R. is funded by a Medical Research Council Centre for Reproductive Health Grant No: MR/N022556/1. A.F. and N.R. received support from a French national research grant PHRC No. 2008/071/HP obtained by the French Institute of Cancer and the French Healthcare Organization. K.E.O. is funded by the University of Pittsburgh Medical Center and the US National Institutes of Health HD100197. V.B-L is supported by the French National Institute of Cancer (Grant Seq21-026). Y.J. is supported by the Royal Children's Hospital Foundation and a Medical Research Future Fund MRFAR000308. E.G., N.N., S.S., C.L.M., A.M.M.v.P., C.E., R.T.M., K.D., M.P.R. are members of COST Action CA20119 (ANDRONET) supported by COST (European Cooperation in Science and Technology). The Danish Child Cancer Foundation is also thanked for financial support (C.Y.A.). The authors declare no competing interests., Trial Registration Number: N/A., Competing Interests: The authors declare no competing interests., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)- Published
- 2024
- Full Text
- View/download PDF
143. Central Venous Catheter-related Bloodstream Infections Caused by Enterobacterales in Pediatric Oncology Patients: Catheter Salvage or Removal.
- Author
-
van den Bosch CH, Kops AL, Loeffen YGT, van der Steeg AFW, van de Wetering MD, Fiocco MF, Ekkelenkamp MB, and Wolfs TFW
- Subjects
- Child, Humans, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Central Venous Catheters adverse effects, Catheterization, Central Venous adverse effects, Sepsis epidemiology, Neoplasms complications, Neoplasms therapy, Catheter-Related Infections drug therapy, Catheter-Related Infections epidemiology, Catheter-Related Infections complications
- Abstract
Background: The aim was to determine whether salvage treatment with systemic antibiotics is a safe and effective strategy for Enterobacterales bloodstream infections (BSI) in pediatric oncology patients with a central venous catheter (CVC)., Methods: A retrospective study was performed on oncology and stem cell recipient patients with a CVC and blood culture with Enterobacterales , at the Princess Máxima Centre for Pediatric Oncology, Utrecht, the Netherlands. Analyses were performed for all BSI and for episodes meeting central line-associated bloodstream infection (CLABSI) criteria. The cumulative incidence of an event (ie, removal, intensive care admission or death) was estimated after blood culture collection for episodes primarily treated with antibiotics. The effect of prognostic factors on the hazard of the event of interest was assessed by estimating a Cox proportional hazard regression model., Results: In total, 95 CVC-related Enterobacterales BSIs in 82 patients were included; 12 (13%) BSIs required immediate CVC removal and for 83 (87%) BSIs CVC salvage was attempted. The cumulative incidence of events at 60 days was 53.0% [95% confidence interval (CI): 41.7-63.1] for BSIs (n = 83), and 64.4% (95% CI: 48.3-76.7) for CLABSIs (n = 45). The events occurred after a median of 6 (Q1-Q3: 2-15) and 6 (Q1-Q3: 2-20) days for BSIs and CLABSIs, respectively. Intensive care admission after salvage treatment was required in 16% of the BSIs and CLABSIs, resulting in death in 5% and 2% of cases, respectively. No significant association between risk factors and events was found., Conclusions: The cumulative incidence of an event at 60 days after salvage treatment for Enterobacterales CLABSIs and BSIs in pediatric oncology patients is high. Immediate CVC removal appears recommendable for this patient group., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
144. Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update.
- Author
-
Patel P, Robinson PD, Phillips R, Baggott C, Devine K, Gibson P, Guilcher GMT, Holdsworth MT, Neumann E, Orsey AD, Spinelli D, Thackray J, van de Wetering M, Cabral S, Sung L, and Dupuis LL
- Subjects
- Adult, Child, Humans, Nausea chemically induced, Nausea drug therapy, Nausea prevention & control, Vomiting chemically induced, Vomiting drug therapy, Vomiting prevention & control, Antiemetics adverse effects, Antineoplastic Agents adverse effects, Neoplasms complications, Neoplasms drug therapy
- Abstract
This clinical practice guideline update provides recommendations for treating breakthrough chemotherapy-induced nausea and vomiting (CINV) and preventing refractory CINV in pediatric patients. Two systematic reviews of randomized controlled trials in adult and pediatric patients informed the recommendations. In patients with breakthrough CINV, escalation of antiemetic agents to those recommended for chemotherapy of the next higher level of emetogenic risk is strongly recommended. A similar recommendation to escalate therapy is made to prevent refractory CINV in patients who did not experience complete breakthrough CINV control and are receiving minimally or low emetogenic chemotherapy. A strong recommendation to use antiemetic agents that controlled breakthrough CINV for the prevention of refractory CINV is also made., (© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
145. CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients.
- Author
-
van den Bosch CH, Loeffen Y, van der Steeg AFW, van der Bruggen JT, Frakking FNJ, Fiocco M, van de Ven CP, Wijnen MHWA, and van de Wetering MD
- Subjects
- Child, Humans, Heparin therapeutic use, Citric Acid, Quality of Life, Citrates, Randomized Controlled Trials as Topic, Central Venous Catheters adverse effects, Catheter-Related Infections prevention & control, Catheter-Related Infections epidemiology, Sepsis prevention & control, Sepsis etiology, Neoplasms complications
- Abstract
Introduction: The efficacy of taurolidine containing lock solutions for the prevention of central line-associated bloodstream infections (CLABSI) in paediatric oncology patients is still unknown. If the taurolidine-citrate-heparin lock appears to decrease the incidence of CLABSIs, we hope to increase the quality of life of children with cancer by subsequently reducing the central venous access device (CVAD)-removal rates, dispense of antibiotics, hospital admissions and incidence of severe sepsis resulting in intensive care unit admission., Methods and Analysis: This assessor-blinded randomised controlled trial including 462 patients was designed to compare the taurolidine-citrate-heparin lock to the heparin-only lock for the prevention of CLABSIs in paediatric oncology patients. Patients receiving their first CVAD at the Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands, are eligible for inclusion. The primary outcome of this study is the incidence of first CLABSIs from CVAD insertion until the end of the study, maximum follow-up of 90 days. An intention-to-treat and a per-protocol analysis will be performed. An interim analysis will be performed after the inclusion of 50% of the patients. The results of the interim analysis and overall conduct of the trial will be discussed by a data safety monitoring board., Ethics and Dissemination: The medical ethics committee NedMec, Utrecht, the Netherlands, has approved this research (number 20/370). Written informed consent for participation in this trial and publication of the trial data is obtained from all patients and/or their parents/guardians. The results of this trial will be published in a peer-reviewed journal and the data will be made available on reasonable request after publication of the main results manuscript., Trial Registration Numbers: NTR6688; NCT05740150., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
146. Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting.
- Author
-
Nijstad AL, de Vos-Kerkhof E, Enters-Weijnen CF, van de Wetering MD, Tissing WJE, Tibben MM, Rosing H, Lalmohamed A, Huitema ADR, and Zwaan CM
- Subjects
- Adult, Child, Humans, Aprepitant therapeutic use, Chromatography, Liquid, Morpholines, Tandem Mass Spectrometry, Nausea chemically induced, Nausea drug therapy, Nausea prevention & control, Vomiting chemically induced, Vomiting drug therapy, Vomiting prevention & control, Dexamethasone, Drug Therapy, Combination, Antiemetics, Antineoplastic Agents adverse effects
- Abstract
Purpose: Chemotherapy-induced nausea and vomiting (CINV) are common side effects in pediatric oncology treatment. Besides 5-HT
3 -antagonists, both dexamethasone and aprepitant are cornerstone drugs in controlling these side effects. Based on results of adult studies, the dexamethasone dose is reduced by 50% when combined with aprepitant, because of a drug-drug interaction, even though data on the interaction in children is lacking. The current study was developed to investigate the effect of aprepitant on dexamethasone clearance (CL) in children, in order to assess if dexamethasone dose reduction for concomitant use of aprepitant is appropriate in the current antiemetic regimen., Methods: In total, 65 children (0.6-17.9 years), receiving intravenous or oral antiemetic therapy (dexamethasone ± aprepitant) as standard of care, were included. 305 dexamethasone plasma concentrations were determined using LC-MS/MS. An integrated dexamethasone and aprepitant pharmacokinetic model was developed using non-linear mixed effects modelling in order to investigate the effect of aprepitant administration on dexamethasone CL., Results: In this population, dexamethasone CL in patients with concomitant administration of aprepitant was reduced by approximately 30% of the uninhibited CL (23.3 L/h (95% confidence interval 20.4-26.0)). This result is not consistent with the results of adult studies (50% reduction). This difference was not age dependent, but might be related to the route of administration of dexamethasone. Future studies are needed to assess the difference in oral/intravenous dexamethasone., Conclusion: When dexamethasone is given intravenously as a component of triple therapy to prevent CINV in children, we advise to reduce the dexamethasone dose by 30% instead of 50%., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
147. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.
- Author
-
Patel P, Robinson PD, Wahib N, Cheung P, Wong T, Cabral S, Parker A, Cohen M, Devine K, Gibson P, Holdsworth MT, Neumann E, Orsey A, Phillips R, Spinelli D, Thackray J, van de Wetering M, Woods D, Sung L, and Dupuis LL
- Subjects
- Adult, Humans, Child, Nausea chemically induced, Nausea prevention & control, Nausea drug therapy, Vomiting chemically induced, Vomiting prevention & control, Vomiting drug therapy, Dexamethasone therapeutic use, Antiemetics therapeutic use, Neoplasms drug therapy, Antineoplastic Agents adverse effects
- Abstract
Purpose: To identify effective and safe interventions to prevent acute phase chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric patients., Methods: We conducted a systematic review of randomized trials evaluating interventions to prevent acute CINV. Outcomes assessed were complete chemotherapy-induced vomiting (CIV) control, complete chemotherapy-induced nausea (CIN) control, complete CINV control, and discontinuation of antiemetics due to adverse effects., Results: The search identified 65,172 citations; 744 were evaluated at full-text, and 295 (25 pediatric) met eligibility criteria. In patients receiving highly emetogenic chemotherapy (HEC), complete CIV (risk ratio (RR) 1.23, 95% confidence interval (CI) 1.05-1.44) and CIN (RR 1.34, 95% CI 1.10-1.62) control improved when olanzapine was added. The addition of a neurokinin-1 receptor antagonist (NK1RA) to a corticosteroid plus a serotonin-3 receptor antagonist (5HT3RA) also improved complete CIV (RR 1.11, 95% CI 1.08-1.14) and CIN (RR 1.05, 95% CI 1.01-1.08) control. Compared to granisetron/ondansetron, palonosetron provided improved complete CIV control when the 5HT3RA was given alone or when combined with dexamethasone. In patients receiving moderately emetogenic chemotherapy (MEC), dexamethasone plus a 5HT3RA improved complete CIV control compared to a 5HT3RA alone (RR 1.29, 95% CI 1.21-1.39). Only a single meta-analysis evaluating the safety outcome was possible., Conclusions: For patients receiving HEC, various antiemetic regimens improved CIV and CIN control. For patients receiving MEC, administration of a 5HT3RA plus dexamethasone improved CIV control. Analysis of antiemetic safety was constrained by lack of data., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
148. Central venous catheter-associated complications in pediatric patients diagnosed with Hodgkin lymphoma: implications for catheter choice.
- Author
-
van den Bosch CH, Spijkerman J, Wijnen MHWA, Hovinga ICLK, Meyer-Wentrup FAG, van der Steeg AFW, van de Wetering MD, Fiocco M, Morsing IE, and Beishuizen A
- Subjects
- Anticoagulants, Child, Humans, Retrospective Studies, Risk Factors, Catheter-Related Infections epidemiology, Catheter-Related Infections etiology, Catheter-Related Infections prevention & control, Catheterization, Central Venous adverse effects, Catheterization, Peripheral adverse effects, Central Venous Catheters adverse effects, Hodgkin Disease complications, Hodgkin Disease drug therapy, Thrombosis etiology, Venous Thrombosis epidemiology, Venous Thrombosis etiology
- Abstract
Purpose: The purpose of this study was to determine the most optimal central venous catheter (CVC) for pediatric patients with Hodgkin lymphoma (HL) in terms of complications., Methods: A retrospective study including patients diagnosed with HL from 2015 to 2021 at the Princess Máxima Center was performed. Patients were followed from CVC insertion until removal or 06-2021, whichever came first. The primary outcome was the CVC-related complication incidence rate (IR) per 1000 CVC-days. Furthermore, the incidence rate ratio (IRR) was calculated by comparing complication IRs between peripherally inserted central catheters (PICC) and totally implantable venous access ports (TIVAP). Additionally, risk factors for central venous thrombosis (CVT) were identified., Results: A total of 98 patients were included. The most frequently observed complications were local irritation/infections (18%; IR 0.93), malfunctions (15%; IR 0.88), and CVC-related CVTs (10%; IR 0.52). Single lumen PICCs were associated with a higher risk of complications (49% vs. 26%; IRR 5.12, CI95% 2.76-9.50), severe complications (19% vs. 7%; IRR 11.96, CI95% 2.68-53.42), and early removal (18% vs. 7%; IRR 9.96, CI95% 2.18-45.47). A single lumen PICC was identified as a risk factor for CVC-related CVT when compared to TIVAPs (12% vs. 7%, IRR 6.98, CI95% 1.45-33.57)., Conclusion: The insertion of a TIVAP rather than a PICC should be recommended for pediatric patients with HL, especially in the presence of CVT-related risk factors. Future trials should evaluate the efficacy and safety of direct oral anticoagulants for the primary prevention of CVT in pediatric patients with a PICC and other CVT-related risk factors., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
149. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
- Author
-
Kemps PG, Picarsic J, Durham BH, Hélias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JAM, Verdijk RM, Flucke UE, Hogendoorn PCW, Woei-A-Jin FJSH, Sciot R, Beilken A, Feuerhake F, Ebinger M, Möhle R, Fend F, Bornemann A, Wiegering V, Ernestus K, Méry T, Gryniewicz-Kwiatkowska O, Dembowska-Baginska B, Evseev DA, Potapenko V, Baykov VV, Gaspari S, Rossi S, Gessi M, Tamburrini G, Héritier S, Donadieu J, Bonneau-Lagacherie J, Lamaison C, Farnault L, Fraitag S, Jullié ML, Haroche J, Collin M, Allotey J, Madni M, Turner K, Picton S, Barbaro PM, Poulin A, Tam IS, El Demellawy D, Empringham B, Whitlock JA, Raghunathan A, Swanson AA, Suchi M, Brandt JM, Yaseen NR, Weinstein JL, Eldem I, Sisk BA, Sridhar V, Atkinson M, Massoth LR, Hornick JL, Alexandrescu S, Yeo KK, Petrova-Drus K, Peeke SZ, Muñoz-Arcos LS, Leino DG, Grier DD, Lorsbach R, Roy S, Kumar AR, Garg S, Tiwari N, Schafernak KT, Henry MM, van Halteren AGS, Abla O, Diamond EL, and Emile JF
- Subjects
- Adolescent, Adult, Anaplastic Lymphoma Kinase genetics, Child, Child, Preschool, Female, Histiocytic Disorders, Malignant complications, Histiocytic Disorders, Malignant genetics, Humans, Infant, Male, Nervous System Diseases etiology, Nervous System Diseases genetics, Nervous System Diseases pathology, Oncogene Proteins, Fusion analysis, Oncogene Proteins, Fusion antagonists & inhibitors, Oncogene Proteins, Fusion genetics, Retrospective Studies, Young Adult, Anaplastic Lymphoma Kinase analysis, Anaplastic Lymphoma Kinase antagonists & inhibitors, Histiocytic Disorders, Malignant drug therapy, Histiocytic Disorders, Malignant pathology, Protein Kinase Inhibitors therapeutic use
- Abstract
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
150. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors.
- Author
-
Frühwald MC, Hasselblatt M, Nemes K, Bens S, Steinbügl M, Johann PD, Kerl K, Hauser P, Quiroga E, Solano-Paez P, Biassoni V, Gil-da-Costa MJ, Perek-Polnik M, van de Wetering M, Sumerauer D, Pears J, Stabell N, Holm S, Hengartner H, Gerber NU, Grotzer M, Boos J, Ebinger M, Tippelt S, Paulus W, Furtwängler R, Hernáiz-Driever P, Reinhard H, Rutkowski S, Schlegel PG, Schmid I, Kortmann RD, Timmermann B, Warmuth-Metz M, Kordes U, Gerss J, Nysom K, Schneppenheim R, Siebert R, Kool M, and Graf N
- Subjects
- Adolescent, Adult, Age Distribution, Child, DNA Methylation, Europe, Female, Humans, In Situ Hybridization, Fluorescence, Male, Risk Factors, Young Adult, Rhabdoid Tumor genetics, Rhabdoid Tumor therapy, Teratoma genetics, Teratoma therapy
- Abstract
Background: Controversy exists as to what may be defined as standard of care (including markers for stratification) for patients with atypical teratoid/rhabdoid tumors (ATRTs). The European Rhabdoid Registry (EU-RHAB) recruits uniformly treated patients and offers standardized genetic and DNA methylation analyses., Methods: Clinical, genetic, and treatment data of 143 patients from 13 European countries were analyzed (2009-2017). Therapy consisted of surgery, anthracycline-based induction, and either radiotherapy or high dose chemotherapy following a consensus among European experts. Fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, and sequencing were employed for assessment of somatic and germline mutations in SWItch/sucrose nonfermentable related, matrix associated, actin dependent regulator of chromatin, subfamily B (SMARCB1). Molecular subgroups (ATRT-SHH, ATRT-TYR, and ATRT-MYC) were determined using DNA methylation arrays, resulting in profiles of 84 tumors., Results: Median age at diagnosis of 67 girls and 76 boys was 29.5 months. Five-year overall survival (OS) and event-free survival (EFS) were 34.7 ± 4.5% and 30.5 ± 4.2%, respectively. Tumors displayed allelic partial/whole gene deletions (66%; 122/186 alleles) or single nucleotide variants (34%; 64/186 alleles) of SMARCB1. Germline mutations were detected in 26% of ATRTs (30/117). The patient cohort consisted of 47% ATRT-SHH (39/84), 33% ATRT-TYR (28/84), and 20% ATRT-MYC (17/84). Age <1 year, non-TYR signature (ATRT-SHH or -MYC), metastatic or synchronous tumors, germline mutation, incomplete remission, and omission of radiotherapy were negative prognostic factors in univariate analyses (P < 0.05). An adjusted multivariate model identified age <1 year and a non-TYR signature as independent negative predictors of OS: high risk (<1 y + non-TYR; 5-y OS = 0%), intermediate risk (<1 y + ATRT-TYR or ≥1 y + non-TYR; 5-y OS = 32.5 ± 8.7%), and standard risk (≥1 y + ATRT-TYR, 5-y OS = 71.5 ± 12.2%)., Conclusions: Age and molecular subgroup status are independent risk factors for survival in children with ATRT. Our model warrants validation within future clinical trials., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.